ReViral

Cell and Gene
Share

ReViral is a UK-based biotechnology company with a portfolio of drugs to treat Respiratory Syncytial Virus (RSV) infection. RSV currently represents a major unmet medical need in children, the elderly and the immuno compromised.

Our most advanced programme, RV521, is a highly potent, orally-administered inhibitor of RSV fusion protein, and has demonstrated top-line safety and pharmacokinetic data in Phase1 single and multiple ascending dose (SAD and MAD) trials. RV521 has successfully completed a Phase 2a proof-of-concept study in adult volunteers. RV521 will start clinical trials in patients in 2018.

Good morning #BIOEurope! @ReViralLtd's Cora Griffin is at @EBDgroup's #BIOEurope in #Hamburg ready for 3 action-packed days of networking and partnering meetings... #biotech #networking #sharingideas #antivirals #rsv pic.twitter.com/nIJANnAGof

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.